Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

BackgroundResults from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients with a squamous ce...

Full description

Bibliographic Details
Main Authors:	Noordman, Bo Jan, Shapiro, Joel, Spaander, Manon CW, Krishnadath, Kausilia K, van Laarhoven, Hanneke WM, van Berge Henegouwen, Mark I, Nieuwenhuijzen, Grard AP, van Hillegersberg, Richard, Sosef, Meindert N, Steyerberg, Ewout W, Wijnhoven, Bas PL, van Lanschot, J Jan B
Format:	Article
Language:	English
Published:	JMIR Publications 2015-06-01
Series:	JMIR Research Protocols
Online Access:	http://www.researchprotocols.org/2015/2/e79/

Internet

http://www.researchprotocols.org/2015/2/e79/

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Internet

Similar Items